Targeted radionuclide therapy for malignant neuroendcrine tumors based on biological and pathohistological characteristics

2014 Fiscal Year Final Research Report

• Project/Area Number: 22390230
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kanazawa University
• Principal Investigator: KINUYA Seigo 金沢大学, 医学系, 教授 (20281024)
• Research Collaborator: KAYANO Daiki 金沢大学, 大学病院, 助教 (10547152) ; INAKI Anri 金沢大学, 医学系, 助教 (40645131) ; WAKABAYASHI Hiroshi 金沢大学, 大学病院, 助教 (60622818)
• Project Period (FY): 2010-04-01 – 2015-03-31
• Keywords: 内照射療法 / 放射性医薬品 / 内用療法 / 悪性神経内分泌腫瘍 / 褐色細胞腫 / 神経芽腫 / I-131 MIBG

Outline of Final Research Achievements

Targeted radiotherapy with I-131 MIBG was conducted for patients with malignant neuroendocrine tumors. Objective response was observed approximately 60% of adult cases. Responders to the first treatment tended to have good prognosis. In addition, repeated treatments were likely related with good prognosis. High dose treatment followed by bone marrow support may induce complete remission in patients with neuroblastoma refractory to chemotherapy. Diagnostic performance was best with scintigrams of therapeutic doses of I-131 MIBG at late time points. SPECT acquisition further improved diagnosis of lesion location. Caffeine may intensify the efficacy of I-131 MIBG therapy although further investigation is required.

Free Research Field

核医学